Introduction {#s0005}
============

A significant event in the tumorigenic transformation of thyroid follicular cells is the constitutive stimulation of a single signaling pathway. This pathway, known the RAS-BRAF-ERK pathway, is triggered by RET/PTC rearrangement [@bb0005]. A high prevalence of *BRAF* point mutations occurs in papillary thyroid cancers (PTCs; about 30--70%) and in anaplastic thyroid carcinomas (ATCs; about 10--40%) [@bb0010]. In PTCs, *BRAF* mutations, RET/PTC rearrangements, and *RAS* mutations are mostly mutually exclusive [@bb0015].

Patients with the most ordinary type of thyroid cancer, PTC, have low hazard of recurrence and high survival. However, some patients with ATC exhibit high levels of invasiveness and metastasis, and do not respond to any chemotherapy, typically dying in a few months [@bb0020], [@bb0025]. Although rare, ATC is the deadliest form of thyroid cancer; its fatality rate is high, with a 20% survival rate 1 year after diagnosis.

Many studies have shown histone deacetylase (HDAC) inhibitors to be effective anticancer agents; therefore, the US Food and Drug Administration (USFDA) has approved the use of such substances for treating several cancer types [@bb0030], [@bb0035]. Some HDAC inhibitors are currently in clinical trials as therapeutic agents alone or in combination with other anticancer drugs [@bb0040]. *N*-hydroxy-7-(2-naphthylthio) hepatonomide (HNHA) is a novel HDAC inhibitor that demonstrates significantly higher anticancer activity than other HDAC inhibitors such as trichostatin A and suberoylanilide hydroxamic acid [@bb0045], [@bb0050], [@bb0055].

The USFDA recently expanded the permitted use of sorafenib in treating advanced thyroid cancer [@bb0060]. Sorafenib is a multi-kinase inhibitor that obstructs different signaling pathways, including Raf kinases, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptors (PDGFRs) [@bb0065]. Furthermore, sorafenib has also been approved for the therapy of advanced renal cell carcinoma (RCC) and various other human cancers, including thyroid cancer [@bb0065], [@bb0070], [@bb0075], [@bb0080]. The anticancer activity of sorafenib occurs via the Raf/Mek/Erk pathway, inducing cell apoptosis and blocking tumorigenesis [@bb0085]. Like HDAC inhibitors, sorafenib suppresses tumorigenesis by translationally restraining the anti-apoptotic Bcl-2 family member, Mcl-1 [@bb0090], [@bb0095]. Recently, Stat3 was shown to be a major kinase-independent target of sorafenib [@bb0100], [@bb0105]. Unfortunately, however, a majority of the patients does not respond to sorafenib and HDAC inhibitors, and several patients who initially do respond subsequently become resistant, with the continuation of tumor progression [@bb0110], [@bb0115]. Consequently, several researchers have sought to target human cancer with a combination of sorafenib and chemotherapy [@bb0120], [@bb0125]. Since most patients with ATC are diagnosed at an advanced stage, there is a desperate need for new cancer therapies. The present study suggests a new clinical approach for ATC treatments by combination therapy with an HDAC inhibitor and sorafenib. The aim of this study was to determine the antitumor activities of HNHA alone and in combination with sorafenib in ATC cells.

Materials and Methods {#s0010}
=====================

Tissue Specimens {#s0015}
----------------

Fresh tumors were obtained from one patient with biochemically and histologically proven advanced metastatic ATC, who was treated at the Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. The tumor tissue were acquired during surgical resection of primary and metastatic ATC sites. The research protocol was approved by the Institutional Review Board of the Thyroid Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine (IRB Protocol: 3--2016-0076).

Tumor Cell Isolation and Primary Culture {#s0020}
----------------------------------------

After resection, tumors were kept in normal saline with antifungal and antibiotic agents. Normal tissue and fat were removed, and the tissues were rinsed with 1× Hanks\' balanced salt solution (HBSS). Tumor tissue was minced with dissociation medium, which contained RPMI-1640 medium (Hyclone, South Logan, UT, USA) supplemented with 20% FBS and 1 mg/mL of type IV collagenase (Sigma-Aldrich, St Louis, MO, USA). Minced and suspended tumor cells were filtered through sterile 70-μm-pore nylon cell strainers (BD Falcon, Franklin Lakes, NJ, USA), rinsed with 50 mL 1× HBSS, and centrifuged at 1400 rpm for 5 min. Cells were resuspended with RPMI-1640 medium containing 10% fetal bovine serum (FBS; Hyclone) and 2% penicillin/streptomycin solution (Gibco, Grand Island, NY, USA). Cell viability was analyzed by the trypan blue dye exclusion method.

Cell Culture {#s0025}
------------

ATC cell lines 8505C, SNU-80, and GSA1 were obtained from the European Collection of Cell Cultures (ECACC, Salisbury, United Kingdom) or the Korea Cell Line Bank (Seoul National University, Seoul, Korea) or by tumor cell isolation from the current patient and grown in RPMI-1640 medium with 10% FBS ([Table 1](#t0005){ref-type="table"}). Authentication was performed by short tandem repeat profiling, karyotyping, and isoenzyme analysis.

Cell Viability Assay {#s0030}
--------------------

Cells were seeded in 96-well plates at 5 × 10^3^ cells per well and incubated overnight to achieve 70% confluency. The indicated drugs were added to achieve final concentrations of 0--100 μM. Cells were then incubated for the indicated time points before the determination of cell viability, using the MTT reagent according to the manufacturer\'s protocol, and absorbance was measured at 490 nm. Data were expressed as percentages of the signal observed in vehicle-treated cells and shown as the mean ± SD of triplicate experiments.

Flow Cytometry Analysis of the Cell Cycle {#s0035}
-----------------------------------------

Cells were treated with HNHA and sorafenib alone or in combination in RPMI-1640 medium containing 10% FBS for 40 h, harvested by trypsinization, and fixed with 70% ethanol. Cells were stained for total DNA, using PBS containing 40 μg/mL propidium iodide and 100 μg/mL RNase I for 30 min at 37°C. Cell cycle distribution was then analyzed in the FACSCalibur Flow Cytometer (BD Biosciences, San Jose, CA, USA). The proportions of cells in the sub-G~0~/G~1,~ G~0~/G~1~, S, and G~2~/M phases were analyzed by FlowJo v8 software for MacOSX (Tree Star, Ashland, OR, USA). This experiment was repeated thrice, and the results were averaged.

Evaluation of Apoptotic Cell Death {#s0040}
----------------------------------

Cells were fixed with 4% paraformaldehyde solution for 48 h and then analyzed using a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) kit (Promega, Madison, WI, USA). The apoptotic cells (fluorescent green) and total cells were counted by fluorescence microscopy. Images were acquired under a confocal microscope (LSM Meta 700, Carl Zeiss, Oberkochen, Germany) and analyzed using the Zeiss LSM Image Browser software, version 4.2.0121.

Immunoblot Analysis {#s0045}
-------------------

Equal amounts of protein (20 μg) were separated by 8--10% SDS-PAGE. The antibodies for p53 and p21 were obtained from Abcam (Cambridge, UK). Apaf-1, CDK 4, CDK 6, cyclin D1, Bcl-2, p-NF-κB, caspase-3, and β-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies for GRP78, PERK, p-PERK, eIF2α, p-eIF2α, ATF4, and CHOP were purchased from Cell Signaling Technology (Danvers, MA, USA).

Human ATC Cell Xenograft {#s0050}
------------------------

Human ATC cells (2.0 × 10^7^ cells/mouse) were cultured in vitro and then injected subcutaneously into the upper left flank region of female BALB/c nude mice. After 7 days, tumor-bearing mice were grouped randomly (*n* = 10/group) and treated with 25 mg/kg HNHA (intraperitoneally) alone, 80 mg/kg sorafenib (orally) alone, or a combination of 6.5 mg/kg HNHA and 25 mg/kg sorafenib, once every 2 days for a total of 10\~ 12 injections. Tumor size was measured every other day using calipers. Tumor volume was estimated using the following formula: L × S/2 (where L is the longest diameter and S is the shortest diameter). Animals were maintained under specific pathogen-free conditions. All experiments were approved by the Animal Experiment Committee of Yonsei University.

In Vivo Toxicity Study {#s0055}
----------------------

In vivo toxicity assays were performed using female BALB/c nude mice. Six-week-old mice were caged for 1 week for acclimatization. Each group of 10 mice was administered HNHA or sorafenib alone or the combination of HNHA plus sorafenib in the previous subsection. The animals were monitored regularly for external signs of toxicity or lethality. All animals were housed in cages with five mice per cage, with a 12-h/12-h light:dark cycle and temperature and humidity of 22 °C and 40--60%, respectively. A standard diet of rodent pellets and tap water (membrane filter-purified and autoclaved) were provided ad libitum.

Immunohistochemistry {#s0060}
--------------------

All tissues were fixed in 10% neutral-buffered formalin and embedded in paraffin wax by standard protocols. Tissue sections (5 μm) were dewaxed, and antigen retrieval was performed in citrate buffer (pH 6), using an electric pressure cooker set at 120 °C for 5 min. Sections were incubated for 5 min in 3% hydrogen peroxide to quench endogenous tissue peroxidase. All tissue sections were counterstained with hematoxylin, dehydrated, and mounted.

Statistical Analysis {#s0065}
--------------------

Statistical analyses were performed using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA). Immunohistochemistry results were subjected to ANOVA followed by a Bonferroni post hoc test. Values are expressed as means ± SD. *P*\<.05 indicated statistical significance.

Results {#s0070}
=======

Synergistic Inhibition by HNHA and Sorafenib in 8505C, SNU-80, and GSA1 Cells {#s0075}
-----------------------------------------------------------------------------

To investigate the anticancer effects of the synergistic interaction between HNHA and sorafenib in combination, as well as their individual effects, on ATC, we assayed 8505C, SNU-80, and GSA1 cell proliferation in the presence and absence of these compounds by MTT assay ([Table 2](#t0010){ref-type="table"}). HNHA or sorafenib treatment alone had a lower IC~50~ in ATC than the combined treatment. Further characterization of the synergistic effect of HNHA and sorafenib on ATC cell viability showed that the combination reduced the viability of ATC cells to a greater extent than by either agent alone. The combination of HNHA and sorafenib suppressed cell proliferation better than either agent used singly ([Figure 1](#f0005){ref-type="fig"},*A*, *C*, and *E*); moreover, this effect was concentration-dependent ([Figure 1](#f0005){ref-type="fig"},*B*, *D*, and *F*).

The HNHA and Sorafenib Combination Significantly Induced Endoplasmic Reticulum Stress-Dependent Cell Cycle Arrest in ATC {#s0080}
------------------------------------------------------------------------------------------------------------------------

Immunoblot analyses of protein levels in ATC (8505C, SNU-80, and GSA1) cell lines indicated that the HNHA and sorafenib combination induced more marked increases in the levels of p53 and p21---well-known arrestors of the cell cycle---and decreases in the levels of cyclins D1, CDK 4, and CDK 6---positive regulators of the cell cycle---as compared with HNHA or sorafenib alone ([Figure 2](#f0010){ref-type="fig"}*A*). We also tested whether these compounds induced endoplasmic reticulum (ER) stress by treating 8505C, SNU-80, and GSA1 cells with HNHA or sorafenib alone or in combination for 24 h and analyzing the expression of GRP78, ATF4, CHOP, PERK, p-PERK, eIF2α, and p-eIF2α by immunoblotting ([Figure 2](#f0010){ref-type="fig"}*B*). The HNHA and sorafenib combination-treated cells showed the highest increase in these markers of ER stress. Flow cytometry was performed to investigate the effects of these compounds on cell cycle progression. The HNHA and sorafenib combination showed the most significant induction of G~0~/G~1~ phase arrest and increase in the sub-G~0~/G~1~ population (*P* \< .05), indicating the induction of cell cycle arrest and cell death in the ATC cell lines ([Figure 2](#f0010){ref-type="fig"}*C*). Thus, the synergistic effect of HNHA and sorafenib most potently induced ER stress, leading to ER stress-dependent apoptosis, cell cycle arrest, and strong inhibition of ATC and PTC cell viability.

The HNHA and Sorafenib Combination Induced Caspase-Mediated Apoptosis of ATC Cell Lines {#s0085}
---------------------------------------------------------------------------------------

To study the pro-apoptotic signaling pathways activated by exposure of ATC cells to HNHA and sorafenib, the expression of pro-apoptotic (Apaf-1) and anti-apoptotic (phosphorylated NF-κB p65 and Bcl-2) members of the Bcl-2 family, as well as the cleavage of caspase-3, were analyzed by immunoblot analysis ([Figure 3](#f0015){ref-type="fig"}*A*). The results showed that the HNHA and sorafenib combination enriched the "pro" form of caspase-3 and induced the cleavage of pro-caspase-3 more potently than did HNHA or sorafenib alone ([Figure 3](#f0015){ref-type="fig"}*A*). The TUNEL assay confirmed that the combination induced apoptosis in ATC cell lines more potently than did either agent alone ([Figure 3](#f0015){ref-type="fig"}, *B*--*D*). These data demonstrated that the synergistic effect of HNHA and sorafenib efficiently induces apoptosis in ATC cells and that it exerts this effect via caspase cleavage and inhibition of the Bcl-2 pathway.

The HNHA and Sorafenib Combination Reduced Xenograft Growth and Improved Survival In Vivo {#s0090}
-----------------------------------------------------------------------------------------

HNHA and sorafenib markedly suppressed 8505C and SNU-80 cell xenograft tumors; however, their combination exhibited a greater suppression of these tumors ([Figure 4](#f0020){ref-type="fig"}, *A*, *E*, and *I*). Mouse survival was prolonged significantly by both agents, but their combination yielded better survival rates ([Figure 4](#f0020){ref-type="fig"}, *B*, *F*, and *J*). No evidence of systemic toxicity or treatment-related death was found in any group. There was no significant effect on the body weight of mice treated with HNHA and sorafenib ([Figure 4](#f0020){ref-type="fig"}, *C*, *G*, and *K*). The combination-treated group showed significantly smaller tumor volumes compared to the groups treated with HNHA or sorafenib alone ([Figure 4](#f0020){ref-type="fig"}, *D*, *H*, and *L*). HNHA and sorafenib synergistically reduced Bcl-2 (anti-apoptotic protein) levels, increased CHOP (ER stress protein) levels, and cleaved caspase to a greater extent than HNHA or sorafenib alone. This implies a more efficient induction of cell cycle arrest and apoptosis due to ER stress in ATC mouse xenografts by the combination treatment ([Figure 4](#f0020){ref-type="fig"}*M*).

The HNHA and Sorafenib Combination Therapy Suppressed Tumor Growth by Down-Regulating the Expression of an Anti-Apoptotic Factor in ATC Xenografts {#s0095}
--------------------------------------------------------------------------------------------------------------------------------------------------

Anti-apoptotic activity is an important factor in the assessment of the biological behavior of tumorigenesis. At present, Bcl-2 is the most useful marker of anti-apoptosis. We detected this marker by immunohistochemical examination of 8505C, SNU-80, and GSA1 cell xenograft tumors and found that the combination-treated group showed the strongest decrease in Bcl-2 expression ([Figure 5](#f0025){ref-type="fig"}, *A*--*C*), further confirming that HNHA and sorafenib combination therapy has potent anticancer activity in the ATC xenograft model.

Discussion {#s0100}
==========

Thyroid cancer is a common endocrine malignancy [@bb0130]. Recent times have witnessed dramatic improvements in the perception of the molecular pathogenesis of this cancer, best explained by the essential roles of certain signaling pathways. The key mechanisms are epigenetic and genetic modifications in these pathways, such as uncontrolled methylation and mutation of genes [@bb0135], [@bb0140]. A great number of these molecular modifications provide clues about novel prognostic and diagnostic therapeutic targets in thyroid cancer, thereby providing immense chances for further study and progress in the development of novel treatment strategies for this cancer.

BRAF, a serine/threonine kinase well-known to stimulate MAPK pathway mutations, has been implicated in melanoma, colon cancer, and thyroid cancer [@bb0015], [@bb0145], [@bb0150]. A high prevalence of BRAF point mutations in PTCs and ATCs has been reported [@bb0010]. However, in thyroid carcinomas, the pathways and molecules connected to the effect of BRAF suppression in cellular survival are poorly understood. Notably, patients with PTC have a low risk of recurrence and high survival, whereas some patients with ATC show considerable metastasis and respond poorly to chemotherapy [@bb0155], [@bb0160], [@bb0165]. Therefore, combinations of targeted therapies that shrink ATCs are warranted.

HDAC inhibitors have been used against ATC cells [@bb0170], [@bb0175], and HNHA has been found to be effective at low doses [@bb0055]. HDACs are histone-modifying enzymes that play major roles in the control of several proteins that are involved in tumorigenesis. Deviant expression of some HDACs has been demonstrated in diverse human cancers [@bb0180]. High HDAC1 expression has been linked with a more advanced tumor--node--metastasis stage, greater cancer cell invasion, and a lower survival rate in human cancers [@bb0185]. Accordingly, HDACs are promising drug targets for treating several human cancers. Some HDAC inhibitors are being investigated for their effects against solid and hematologic malignancies [@bb0190]. HDAC inhibitors are also being assessed in combination with radiotherapy, chemotherapy, and molecular targeted agents [@bb0040], [@bb0195]. In an earlier study, we reported the anticancer activity of HNHA, an *N*-hydroxyacrylamide-derived HDAC inhibitor, in ATC and PTC cell lines [@bb0055]. Furthermore, in ATC and PTC tumor xenograft models, HNHA was demonstrated to be more effective than established HDAC inhibitors in suppressing tumor growth without triggering body weight loss [@bb0055].

Sorafenib is an established multi-kinase inhibitor with activity against the Ser/Thr kinase Raf, which plays a crucial role in tumor cell proliferation and signaling, as well as angiogenesis-related receptor tyrosine kinases such as VEGFR2 and PDGFR [@bb0065], [@bb0200], [@bb0205]. Sorafenib also targets the Raf/Mek/Erk pathway. One study proved that patients with high levels of p-Erk have a greater survival rate [@bb0070], [@bb0085]. The use of this multi-kinase inhibitor was recently permitted for the therapy of advanced thyroid cancer [@bb0210]. In the present study, we found that the combination therapy of HNHA and sorafenib had a lower IC~50~ in ATC than that of either agent alone. The mechanisms underlying these synergistic anticancer effects of both agents on ATC cell lines included the induction of cell cycle arrest and apoptosis. Apoptosis was shown by the increased proportion of cells in sub-G~1~ and by the stimulation of caspase 3. The combination therapy also demonstrated a characteristic effect on cell cycle progression, whereby G~1~ arrest was evident in the presence of lower concentrations of HNHA and sorafenib, as compared to the levels of HNHA or sorafenib that individually produced this effect. This finding was consistent with those of previous studies showing that HNHA or sorafenib when used alone are cytotoxic and induce G~1~ arrest at lower concentrations [@bb0055], [@bb0070], [@bb0215].

This study showed synergistic cytotoxic effects of combined HNHA plus sorafenib therapy on ATC cell lines, both in vitro and in vivo. The combination therapy induced a more marked rise in the apoptosis of ATC cells than did HNHA or sorafenib singly. Consistent with this, the capacity of HDAC inhibitors to induce p21 expression has been described in a number of cell types and has been shown to occur through promoter hyperacetylation [@bb0220]. The inhibition of p21 expression affects the lethality of HDAC inhibitors and DNA-damaging agents in various cancer cell types, such as leukemia, thyroid cancer, and RCC [@bb0050], [@bb0055], [@bb0225], [@bb0230], [@bb0235]. It has been suggested that p21 is cleaved by caspase-3 for DNA injury-mediated apoptosis [@bb0240]. Sorafenib-mediated transcriptional suppression may cause the down-regulation of p21. Besides its role as a cyclin-mediated kinase inhibitor, some investigations propose that p21 might engage in DNA repair by controlling the interaction between PARP-1 and base excision repair factors, thereby participating in resistance to chemotherapeutic agents [@bb0245], [@bb0250]. Therefore, it will be interesting to investigate whether the sorafenib-mediated down-regulation of p21 causes the synergistic interaction between HNHA and sorafenib.
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![Combination of HNHA and sorafenib suppressed ATC cell proliferation more efficiently than either agent alone. Cell viability and proliferation assay of HNHA and sorafenib combined and HNHA and sorafenib alone in ATC cells (8505C, A and B; SNU-80, C and D; GSA1, E and F). Points indicate mean % of the value observed in the solvent-treated control. All experiments were repeated at least 3 times. The data represent the mean ± SD. Experiments were repeated at least 3 times with similar results. \* *P* \< .05 vs. control, \*\* *P* \< .01 vs. control, \*\*\* *P* \< .005 vs. control.](gr1){#f0005}

![Combination of HNHA and sorafenib induced cell cycle arrest and endoplasmic reticulum stress in ATC cells more potently than either agent alone. Immunoblot analysis of the indicated cell lines following exposure to the HNHA and sorafenib combination or each agent singly. The HNHA and sorafenib combination potently induced the expression of cell cycle arrest proteins and reduced the expression of positive regulators of the cell cycle (A). 8505C, SNU 80, and GSA1 were exposed to the indicated inhibitors for 24 h prior to the analysis of the expression of GRP78, ATF4, CHOP, PERK, p-PERK, eIF2α, and p-eIF2α (markers of endoplasmic reticulum stress) by immunoblot analysis (B). Cells were exposed to the indicated inhibitors, harvested, and stained with propidium iodide before analysis by flow cytometry and FlowJo v8 software (C).](gr2){#f0010}

![Combination of HNHA and sorafenib significantly induced apoptotic death in ATC cells. Immunoblot analyses suggested that the indicated inhibitors increased the levels of apoptotic proteins and reduced those of anti-apoptotic proteins in ATC cells (A). TUNEL assay of ATC cells; TUNEL-positive (apoptotic) cells are indicated (×400) (B, 5805C; C, SNU-80; and D, GSA1).](gr3){#f0015}

![Combination of HNHA and sorafenib produced antitumor effects in ATC cell xenografts in vivo. Athymic nude mice with established tumors were treated with the indicated inhibitors. Data represent the mean tumor volumes. HNHA and sorafenib combination therapy induced more potent inhibition of tumor progression than did HNHA or sorafenib alone, resulting in the maximum prolongation of survival in mice with ATC (8505C, A--D; SNU-80, E--H; and GSA1, I--L) xenografts (*n* = 10 mice/group) (A, E, and I). "No tumor + HNHA + sorafenib" indicates HNHA and sorafenib combination-treated mice with no xenograft; no evidence of systemic toxicity or treatment-related death was found in HNHA and sorafenib combination-treated groups (B, F, and J). The compounds had no significant effect on mouse body weight (C, G, and K). Weights of the dissected tumors (D, H, and L). Immunoblot analysis of total proteins isolated from the tumors (M). \* *P* \< .05 vs. control, \*\* *P* \< .01 vs. control, \*\*\* *P* \< .005 vs. control.](gr4){#f0020}

![HNHA and sorafenib combination therapy significantly reduced tumor Bcl-2 expression. Immunohistochemical analysis of the Bcl-2 protein levels in paraffin-embedded tumor tissues from mice with ATC xenografts. Synergistic activity of the HNHA and sorafenib combination induced more potent inhibition of tumor Bcl-2 expression than HNHA or sorafenib did alone. MetaMorph 4.6 image-analysis software was used to quantify Bcl-2 immunostaining. \* *P* \< .05; \*\* *P* \< .01; \*\*\* *P* \< .005 for the comparison with the control.](gr5){#f0025}

###### 

Cell line characteristics, viability after drug treatment of all thyroid carncer cell lines examined

Table 1

                                                8505C                       SNU-80                      GSA1
  --------------------------------------------- --------------------------- --------------------------- ------------------------------------------
  Age at diagnosis                              78                          59                          74
  Gender                                        Female                      Female                      Female
  Primary disease site                          Thyroid                     Thyroid                     Thyroid
  Stage                                         \-                          \-                          IVc
  Primary pathology                             Anaplastic thyroid cancer   Anaplastic thyroid cancer   Anaplastic thyroid cancer
  Classification of specimen used for culture   \-                          \-                          Fresh tumor
  Obtained from                                 ECACC                       Korea Cell Line Bank        Gangnam Severance Hospital, Seoul, Korea

###### 

IC50 (half maximal inhibitory concentration) determination using a cell proliferation assay

Table 2

  Cell line   Hisopathology                Animal   Cell proliferation IC~50~^⁎^ (μM)                  
  ----------- ---------------------------- -------- ----------------------------------- -------------- --------------
  8505C       Thyroid cancer: anaplastic   Human    3.82 (±0.5)\*                       17.42 (±0.6)   10.21 (±0.9)
  SNU-80      Thyroid cancer: anaplastic   Human    0.87 (±1.1)\*                       2.28 (±0.4)    5.14 (±1.1)
  GSA1        Thyroid cancer: anaplastic   Human    8.72 (±0.5)\*                       20.14 (±0.5)   23.45 (±0.6)

HNHA and sorafenib combination treatment is a lower IC50 than HNHA or sorafenib alone. Each data point represents the mean of 3 independent MTT assays for IC50 performed in triplicate. SD, standard deviation.
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